Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition

Vivos Therapeutics

19/11/2025 21:30

Overview

Vivos Q3 2025 revenue rises 76% yr/yr, driven by SCN acquisition

Company's gross margin declines to 58% from 60% due to pricing discounts

Operating expenses increase 74% due to SCN acquisition-related costs

Outlook

Vivos expects near-term expenses to rise due to investments in SCN operations

Company plans to expand sleep center model beyond Las Vegas

Vivos anticipates seeing patients at new Michigan location by December

Result Drivers

SCN ACQUISITION IMPACT - Vivos attributes 78% sequential revenue growth to the acquisition of The Sleep Center of Nevada

STRATEGIC PIVOT - Co's shift from dental distribution to direct medical affiliations drives revenue increase

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$5.4 mln
Q3 Gross Profit
$3.94 mln
Q3 Operating Income
-$4.73 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Vivos Therapeutics Inc is $6.50, about 62% above its November 18 closing price of $2.47

Press Release: ID:nGNX32j7qg

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)